Strs Ohio Invests $1 Million in Insulet Corporation $PODD

Key Points

• Strs Ohio has made a new investment of approximately $1 million in Insulet Corporation (NASDAQ:PODD), acquiring 3,822 shares in the process.
• Insulet has shown strong performance, reporting $649.10 million in revenue for the last quarter, a 32.9% increase year-over-year, along with earnings per share of $1.17 that surpassed expectations.
• Several institutional investors significantly increased their stakes in Insulet, with Acadian Asset Management lifting its holdings by 374.1%, now owning over 54,000 shares valued at approximately $14.3 million.

Strs Ohio bought a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,822 shares of the medical instruments supplier's stock, valued at approximately $1,004,000.

Several other large investors have also made changes to their positions in the company. Larson Financial Group LLC increased its position in Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 81 shares in the last quarter. Zions Bancorporation National Association UT bought a new stake in shares of Insulet in the first quarter worth about $26,000. SouthState Corp increased its holdings in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 76 shares in the last quarter. Ramirez Asset Management Inc. bought a new stake in shares of Insulet in the first quarter worth $53,000. Finally, NewEdge Advisors LLC grew its stake in shares of Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock valued at $54,000 after buying an additional 64 shares in the last quarter.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PODD. Oppenheimer raised their price target on shares of Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. Truist Financial initiated coverage on Insulet in a report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Piper Sandler boosted their target price on shares of Insulet from $320.00 to $360.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. Royal Bank Of Canada raised their target price on Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Finally, Raymond James Financial reiterated an "outperform" rating and set a $360.00 price objective (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $343.06.

Insulet Trading Up 1.3%

Insulet stock traded up $4.28 during midday trading on Monday, reaching $335.12. The stock had a trading volume of 431,486 shares, compared to its average volume of 593,672. The firm has a market cap of $23.59 billion, a price-to-earnings ratio of 101.86, a price-to-earnings-growth ratio of 2.75 and a beta of 1.36. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The company has a fifty day moving average of $316.00 and a 200 day moving average of $295.09.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same period last year, the business earned $0.55 EPS. The company's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.